1
|
Zhang Y, Qi D, Gao Y, Liang C, Zhang Y, Ma Z, Liu Y, Peng H, Zhang Y, Qin H, Song X, Sun X, Li Y, Liu Z. History of uses, phytochemistry, pharmacological activities, quality control and toxicity of the root of Stephania tetrandra S. Moore: A review. JOURNAL OF ETHNOPHARMACOLOGY 2020; 260:112995. [PMID: 32497674 DOI: 10.1016/j.jep.2020.112995] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Revised: 05/17/2020] [Accepted: 05/17/2020] [Indexed: 06/11/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE the root of Stephania tetrandra S. Moore, known as Fangji in China (Chinese: ), is a traditional Chinese medicine (TCM) with a long history of use. Fangji is a type of medicine used to treat various diseases, including rheumatism, arthralgia, edema and beriberi, unfavorable urination, and eczema. AIM OF THIS REVIEW There are many newly published reports on the history of uses, phytochemistry, pharmacological activity, quality control and toxicity of Fangji; however, no comprehensive systematic review exists. Therefore, the purpose of this review is to compile the latest and most comprehensive information on Fangji and provide a scientific basis for future research. MATERIALS AND METHODS A systematic literature search was conducted using multiple electronic databases, including SciFinder, Web of Science, PubMed, Science Direct, ACS Publications, J-stage, SpringerLink, Thieme, Wiley, and CNKI. Information was also collected from journals and Chinese Pharmacopoeia. RESULT Thus far, there were uses of Fangji against 20 different diseases/disorders, such as relieving edema and rheumatism pain, treating cough and asthma, treating enuresis, astringent urine and beriberi edema, purging blood and damp heat, and dispelling wind evil and dampness, etc. 48 compounds have been isolated from Fangji, belonging to alkaloids, flavonoids, and steroids, other compounds. The crude extracts and isolated compound of Fangji have shown a wide range of pharmacological activities, such as anti-tumor, anti-inflammatory, and neuroprotective activities, as well as role in reoxygenation, and antimicrobial effect, etc. Moreover, qualitative and quantitative analyses of quality control are reviewed, including qualitative analyses for the identification of compounds, as well as fingerprint and quantitative analyses by high performance liquid chromatography (HPLC) and capillary electrochromatography (CE). In the toxicity study, the hepatotoxicity, hepatorenal toxicity, nephrotoxicity, subacute and acute toxicities of the alcohol extract and water extract of Fangji, and tetrandrine were studied in-vitro and in-vivo experiments. CONCLUSION In the history of uses, Fangji can be used to treat a variety of diseases, most of which are manifested in removing wind and dampness. In recent years, the phytochemistry of Fangji has rarely been reported. The pharmacological activities of Fangji mainly focus on the compounds, tetrandrine and fangchinoline, and there are a few reports on the pharmacological studies of other compounds in Fangji. Moreover, the quality control of Fangji lacks a standard fingerprint to distinguish Fangji from other easily-confused medicinal materials. In the toxicity study, there is no report on the mechanism of toxicity research. Therefore, further studies on such mechanisms are needed.
Collapse
Affiliation(s)
- Yuelin Zhang
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
| | - Dongli Qi
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
| | - Yanquan Gao
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
| | - Chunxia Liang
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
| | - Yukun Zhang
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
| | - Zhe Ma
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
| | - Yiting Liu
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
| | - Hui Peng
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
| | - Ying Zhang
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
| | - Huan Qin
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
| | - Xunan Song
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
| | - Xinru Sun
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
| | - Yingpeng Li
- School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
| | - Zhidong Liu
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
| |
Collapse
|
2
|
Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, Zhao JM, Yu J. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand J Gastroenterol 2009; 44:358-65. [PMID: 18991162 DOI: 10.1080/00365520802530861] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVE Currently, no agent has been confirmed as preventing the fibrosing progression of non-alcoholic steatohepatitis (NASH). In this study, rosiglitazone was used in the clinical treatment of insulin resistance in patients with type 2 diabetes mellitus. However, its protective effect on non-alcoholic fibrosing steatohepatitis is not clear. The study aimed to elucidate the effect and the mechanism of rosiglitazone in inhibiting nutrition-related fibrosis in mice. METHODS C57BL6/J mice were fed a high fat, methionine-choline deficient (MCD) diet for 8 weeks to induce hepatic fibrosis, and rosiglitazone was given in the treated group. The effect of rosiglitazone was assessed by comparing the severity of hepatic fibrosis in liver sections, the activation of hepatic stellate cells (HSCs) and the expression of TGF-beta1 and connective tissue growth factor (CTGF). RESULTS At week 8, MCD-diet-induced fibrosing NASH models showed increased serum ALT and AST levels, severe hepatic steatosis, and infiltration of inflammation and fibrosis which, associated with down-regulated PPAR gamma mRNA and protein expression, up-regulated alpha-SMA protein expression and enhanced TGF-beta1, CTGF mRNA and protein expression. Rosiglitazone significantly lowered serum ALT and AST and it reduced MCD-induced fibrosis by repressing levels of alpha-SMA protein expression and pro-fibrosis factors TGF-beta1 and CTGF. It also restored expression of PPAR gamma. CONCLUSIONS The present study provides clear morphological and molecular biological evidence of the protective role of rosiglitazone in ameliorating nutritional fibrosing steatohepatitis. Rosiglitazone may ameliorate hepatic fibrosis by activating PPAR gamma, which can inhibit HSC activation and suppress TGF-beta1 and CTGF expression.
Collapse
Affiliation(s)
- Yue-Min Nan
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China.
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Fu DC, Yang SZ, Sun YW, Yu CY, Mao LZ, Jiang XL, Guan RF. Effect of Jiazhu on α-SMA and TGF-β1 expression in rats with hepatic fibrosis. Shijie Huaren Xiaohua Zazhi 2008; 16:253-258. [DOI: 10.11569/wcjd.v16.i3.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the effect of Jiazhu on α-SMA and TGF-β1 expression in the liver of rats with hepatic fibrosis and its anti-fibrosis mechanism.
METHODS: A model of rat hepatic fibrosis was induced by injecting 40% CCl4, which was interfered with high [2.0 g/(kg·d)], medium [1.0 g/(kg·d)] and low doses [0.5 g/(kg·d)] of Jiazhu. Hepatic function and serum TGF-β1 were examined. Expression of α-SMA and TGF-β1 was detected by immunohistochemistry and RT-PCR.
RESULTS: Compared with the model group, the levels of aspartate transaminase and alanine transaminase were significantly decreased in the high, medium and low Jiazhu dose groups. Total protein and albumin increased while serum bilirub and TGF-β1 were significantly reduced. The expression of α-SMA and TGF-β1 in liver tissue was decreased. The mRNA expression, stained area and gray scale of α-SMA and TGF-β1 in the high, medium and low Jiazhu dose groups were significantly different compared with the model group(α-SMA: 9.21 ± 1.12、12.63 ± 2.42、14.23 ± 1.57 vs 16.32 ± 2.14, P < 0.01、P < 0.01、P < 0.05; TGF-β1 mRNA: 5.58 ± 0.80、8.62 ± 1.16、11.92 ± 1.35 vs 14.57±1.59, P < 0.01、P < 0.01、P < 0.01), (dyeing area of α-SMA: 9.21% ± 1.29%、12.63% ± 1.44%、14.23% ± 1.41% vs 16.32% ± 1.75%, P < 0.01、P < 0.01、P < 0.05; dyeing area of TGF-β1: 5.31% ± 0.70%、8.37% ± 1.09%、11.92% ± 1.42% vs 14.47% ± 1.48%, P < 0.01、P < 0.01、P < 0.01), (gray scale of α-SMA: 91.29 ± 9.53、99.55 ± 11.83、107.18 ± 12.06 vs 116.44 ± 12.97, P < 0.01、P < 0.01、P < 0.05; gray scale of TGF-β1: 89.96 ± 9.64、106.92 ± 13.90、110.50 ± 12.91 vs 127.13 ± 14.88, P < 0.01、P < 0.01、P < 0.05).
CONCLUSION: Jiazhu can inhibit rat hepatic fibrosis induced by CCL4.
Collapse
|
4
|
Luk JM, Wang X, Liu P, Wong KF, Chan KL, Tong Y, Hui CK, Lau GK, Fan ST. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int 2007; 27:879-90. [PMID: 17696925 DOI: 10.1111/j.1478-3231.2007.01527.x] [Citation(s) in RCA: 93] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Liver disease afflicts over 10% of the world population. This includes chronic hepatitis, alcoholic steatosis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC), which are the most health-threatening conditions drawing considerable attention from medical professionals and scientists. Patients with alcoholism or viral hepatitis are much more likely to have liver cell damage and cirrhosis, and some may eventually develop HCC, which is unfortunately, and very often, a fatal malignancy without cure. While liver surgery is not suitable in many of the HCC cases, patients are mostly given palliative support cares or transarterial chemoembolization or systemic chemotherapies. However, HCC is well known to be a highly chemoresistant tumour, and the response rate is <10-20%. To this end, alternative medicines are being actively sought from other sources with hopes to halt the disease's progression or even eliminate the tumours. Traditional Chinese herbal medicine has begun to gain popularity worldwide for promoting healthcare as well as disease prevention, and been used as conventional or complementary medicines for both treatable and incurable diseases in Asia and the West. In this article, we discuss the laboratory findings and clinical trial studies of Chinese herbal medicines (particularly small molecule compounds) for the treatment of liver disease ranging from fibrosis to liver cancer.
Collapse
Affiliation(s)
- John M Luk
- Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong.
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Piao XX, Huang HG, Piao DM. Therapeutic role of ethanolic extract of Boschniakia Rossica in dimethylnitrosamine-induced liver fibrosis in rats. Shijie Huaren Xiaohua Zazhi 2005; 13:2205-2209. [DOI: 10.11569/wcjd.v13.i18.2205] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To study the effect of Boschniakia Rossica ethanolic extract (BREE) in rat liver fibrosis induced by dimethylnitrosamine (DMN).
METHODS: Hepatic fibrosis was induced by DMN administration intraperitoneally. Thirty-five male Wistar rats were randomly divided into three groups: normal control group (GA, n = 10), hepatic fibrosis model group (GB, n = 15) and BREE treatment group (GC, n = 10). From the 1st to 3rd wk, rats in GB and GC were treated with DMN (10 g/L) intraperitoneally in the first three days of each week, while rats in GA were treated with normal saline. From the 4th to 7th wk, rats in GC were treated with 50 g/L BREE (10 mL/kg) intragastrically each day, while rats in GA and GB were treated with normal saline. At the 1st d of the 8th wk, all the rats were sacrificed and the activity of superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX), the contents of malondialdehyde (MDA), hyaluronic acid (HA), type Ⅲ procollagen (PC Ⅲ), type Ⅳ collagen (Ⅳ.C) in serum were examined. The expression of alpha smooth muscle actin (α-SMA) in liver was also analyzed.
RESULTS: The activity of SOD (98.58±17.36 kNU/L, 9.99±1.69 kNU/L) and GSH-PX (117.37±45.24 U, 12.43±2.99 U) in serum and liver tissue in GB was significantly lower than those in GA (SOD: 129.05±18.55 kNU/L, 19.94±5.87 kNU/L; GSH-PX: 173.79±25.76 U, 22.66±6.99 U)(P < 0.01), while the contents of MDA in GB (10.87±1.23 μmol/L, 1.38±0.37 μmol/L) were higher than those in GA (6.63±1.05 μmol/L, 0.91±0.25 μmol/L)(P < 0.01). The concentrations of serum HA (394.83±103.28 μg/L), PC Ⅲ (13.30±1.88 mg/L) and Ⅳ.C (2.43±1.32 mg/L) in GB were markedly higher than those in GA (186.54±39.87 μg/L, 6.99±1.55 mg/L, 1.18±0.79 mg/L, P < 0.01). The concentrations of serum HA (115.87±13.96 μg/L), PC Ⅲ (6.67±1.86 mg/L) and Ⅳ.C (1.62±0.50 mg/L) in GC were significantly lower than those in GB (P < 0.05), while the activity of SOD (134.29±21.93 kNU/L, 18.99±6.86 kNU/L) and GSH-PX (171.82±37.50 U, 23.57±7.19 U) in serum and liver tissue increased significantly (P < 0.01). The contents of MDA in serum and tissue in GC (8.68±2.32 μmol/L, 0.97±0.22 μmol/L) was lower than those in GB (10.87±1.23, 1.38±0.37 μmol/L)(P < 0.01). The fibrosis index and α-SMA expression in liver decreased in GC too.
CONCLUSION: BREE plays an anti-fibrogenic role in the DMN-induced liver fibrosis of rat by its anti-oxidative effect and inhibition on hepatic stellate cells activation.
Collapse
|